Publication:
The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma

Simple item page
dc.contributor.authorZhu, Xiaoqun
dc.contributor.authorHe, Lu
dc.contributor.authorZheng, Zhong
dc.contributor.authorWang, Ya
dc.contributor.authorYang, Jun
dc.contributor.authorZhang, Biao
dc.contributor.authorWang, Chaoshan
dc.contributor.authorLi, Zhiwen
dc.date.accessioned2024-10-08T08:46:17Z
dc.date.available2024-10-08T08:46:17Z
dc.date.issued2024
dc.description.abstractBackground. The current selection criteria of patients with stage II colorectal carcinoma (CRC) suitable for adjuvant therapy are not satisfactory. Enhancer of zeste homolog 2 (EZH2) has been demonstrated to be over-expressed in CRC. However, data regarding the role of EZH2 in CRC survival remains controversial, and little is known about it in stage II CRC. Thus, we conducted this study to investigate the clinical significance of EZH2 expression in stage II CRC. Methods. Cases with stage II CRC resected between 2015 and 2018 were retrospectively reviewed. EZH2 expression was analyzed by immunohistochemistry using tissue microarrays. The relationship between EZH2 expression and clinicopathological variables was analyzed. Survival curves were estimated by the KaplanMeier approach. Results. We found high EZH2 expression in 134 of 221 analyzable stage II tumors (60.63%). No significant associations were observed between EZH2 expression and common clinicopathological factors. Survival analyses showed that cases receiving surgery alone had inferior overall survival (OS) than those receiving surgery and chemotherapy (P=0.0075) in stage II CRC with high EZH2 expression, however, metastasis-free survival (MFS) was similar between these two subgroups. Treatment choice had no impact on the survival of stage II CRC with low EZH2 expression. Conclusion. The OS of stage II CRC with high EZH2 expression improved more strikingly with surgery and adjuvant chemotherapy than with surgery alone, which suggests the potential of EZH2 expression as a biomarker to help identify a subgroup of early-stage CRC benefiting from surgery and adjuvant chemotherapy. More large-scale studies are warranted to corroborate this finding and to further evaluate the predictive nature of EZH2.es
dc.formatapplication/pdfes
dc.format.extent9es
dc.identifier.citationHistology and Histopathology, Vol.39, nÂş10, (2024)
dc.identifier.doihttps://doi.org/10.14670/HH-18-732
dc.identifier.issn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/144741
dc.languageenges
dc.publisherUniversidad de Murcia. Departamento de BiologĂ­a Celular e HistologĂ­aes
dc.relationSin financiaciĂłn externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEZH2es
dc.subjectColorectal adenocarcinomaes
dc.subjectImmunohistochemistryes
dc.subjectOverall survivales
dc.subjectSurgeryes
dc.subjectAdjuvant chemotherapyes
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - PatologĂ­a. Medicina clĂ­nica. OncologĂ­aes
dc.titleThe potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinomaes
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Zhu-39-1371-1379-2024.pdf
Size:
4.5 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.39,nÂş10 (2024)